Proteomic exploration of disease mechanisms related to the novel biomarker CCN1 for prediction of death in patients with dilated cardiomyopathy
- Project term
11/2021 - 11/2022
- Granted budget
- Research resource used
Resource liquid samples/image data
Risk stratification, biomarker, heart failure, proteomics
- Principal Investigator
Klingenberg, Roland and Dörr, Marcus (Kerckhoff-Klinik, Dept. of Cardiology and Klinik und Poliklinik für Innere Medizin B, Universitätsmedizin Greifswald)
Phenotyping in heart failure using a proteomic approach constitutes the next frontier and may enable the identification of novel biomarkers and new therapeutic targets.
We have identified CCN1 as a novel circulating biomarker in cardiovascular patients with Acute Coronary Syndromes and patients with Dilated Cardiomyopathy. In both clinical settings, CCN1 constitutes an independent prognostic biomarker to predict death. We now aim to replicate our findings on the prognostic value of CCN1 in a validation cohort from the DZHK Heart Bank. To gain novel insights into what disease process this biomarker reflects and how this impacts mortality, we aim to perform a comprehensive analysis of the proteins involved. Detailed insights into the pathophysiology are a prerequisite to identify potential targets amenable to future therapies.